Celgene hands over $101M in cash to launch a research collaboration with protein player Vividion
A year after Vividion Therapeutics debuted with a $50 million launch round and a platform tech centered on drugging a whole slate of undruggable proteins, the San Diego-based biotech has picked up its first big biopharma collaboration with Celgene.
Celgene is paying a hefty $101 million upfront in a fee plus equity deal to see how Vividion’s R&D engine can work for them in oncology, inflammation and neurodegeneration — a nascent field for them.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
